Pancreatic Cancer Research

ResearcherTianjin Medical University Cancer Institute and HospitalActive in the last 2 years

Shaofei Chang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0009-1306-1279; OpenAlex author ID A5070711806. Sources: OpenAlex.

Their work

Papers
14 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2023: 9 papers · 2024: 4 papers · 2025: 1 paper

Papers 14

  1. Integrated pretreatment stratification system for pancreatic cancer: combining anatomical resectability and tumor biological parameters. Co-author DOI 10.20892/j.issn.2095-3941.2025.0213↗
  2. Survival outcomes of adjuvant chemotherapy in patients with stage I pancreatic cancer stratified by pathologic risk. Co-author DOI 10.1016/j.surg.2024.07.047↗
  3. Nomogram model for predicting early recurrence for resectable pancreatic cancer: A multicenter study. Co-author DOI 10.1097/md.0000000000037440↗
  4. Fibrinogen to pre-albumin ratio is an independent prognostic index for patients with pancreatic ductal adenocarcinoma after radical resection. Co-author DOI 10.1186/s12957-024-03524-0↗
  5. Prognostic significance of grade of malignancy based on histopathological differentiation and Ki-67 in pancreatic ductal adenocarcinoma. Co-author DOI 10.20892/j.issn.2095-3941.2023.0363↗
  6. Biological risk based on preoperative serum CA19-9 and histological grade predicts prognosis and improves accuracy of classification in patients with pancreati… Co-author DOI 10.1002/cnr2.1911↗
  7. Prognostic nutritional score based on pretreatment lymphocyte, platelet, and prealbumin predicts prognosis in patients with pancreatic cancer. Co-author DOI 10.1002/jso.27362↗
  8. A new staging system for postoperative prognostication in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2023.107589↗
  9. Elevated preoperative plasma D-dimer level was an independent prognostic factor for patients with PDAC after curative resection: a retrospective analysis. Co-author DOI 10.1093/jjco/hyad090↗
  10. Nuclear GRP78 Promotes Metabolic Reprogramming and Therapeutic Resistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-23-1143↗
  11. Impact of preoperative CA19-9 and histology grade on prognosis of pancreatic ductal adenocarcinoma and its value in TNM stage Co-author DOI 10.21203/rs.3.rs-2653528/v1↗
  12. Biological risk based on preoperative serum CA19-9 and histology grade predicts prognosis in patients with pancreatic cancer Co-author DOI 10.22541/au.168681252.23358138/v1↗
  13. Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study. Co-author DOI 10.3389/fonc.2023.1276037↗
  14. Presence of tumor deposits is an indicator of poor prognosis in patients with pancreatic ductal adenocarcinoma. First author PMID 37293176↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuexiang Liang · 12 shared papers, 2023–2025 · strength 2.62
  2. Quan Man · 9 shared papers, 2023–2025 · strength 1.95
  3. Tiansuo Zhao · 7 shared papers, 2023–2025 · strength 1.38
  4. Song Gao · 6 shared papers, 2023–2025 · strength 1.32
  5. Yiping Zou · 5 shared papers, 2023–2025 · strength 1.07
  6. Jihui Hao · 5 shared papers, 2023–2025 · strength 0.98
  7. Haorui Li · 4 shared papers, 2023 · strength 0.79
  8. Xiuchao Wang · 3 shared papers, 2023–2025 · strength 0.59
  9. Song Gao · 2 shared papers, 2024–2025 · strength 0.44
  10. Chuntao Gao · 2 shared papers, 2023–2024 · strength 0.36
  11. Junjin Wang · 1 shared paper, 2024 · strength 0.26
  12. Jun Yu · 1 shared paper, 2025 · strength 0.23
  13. Chuntao Gao · 1 shared paper, 2023 · strength 0.22
  14. Li Zhifei · 1 shared paper, 2023 · strength 0.22
  15. Guannan Sheng · 1 shared paper, 2024 · strength 0.21
  16. Yongjie Xie · 1 shared paper, 2024 · strength 0.19
  17. Xugang Sun · 1 shared paper, 2023 · strength 0.17
  18. Xiangyu Kong · 1 shared paper, 2023 · strength 0.17
  19. Fanyang Kong · 1 shared paper, 2023 · strength 0.17
  20. Qihui Sun · 1 shared paper, 2023 · strength 0.17
  21. Fang Wei · 1 shared paper, 2023 · strength 0.17
  22. Keping Xie · 1 shared paper, 2023 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.